Does Aetna Cover Tirzepatide for Weight Loss? The 2026 Coverage Map and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Aetna covers Mounjaro (tirzepatide for diabetes) on most commercial plans with prior authorization, but excludes Zepbound (tirzepatide for weight loss) on 78% of employer-sponsored plans as of April 2026
• The coverage gap exists because most Aetna plans explicitly exclude anti-obesity medications under pharmacy benefit carve-outs, even when the same molecule is covered for diabetes
• Medicare Advantage plans administered by Aetna cannot cover weight-loss medications by federal law, though this may change if the Treat and Reduce Obesity Act passes
• Compounded tirzepatide costs $297 to $399 per month through platforms like FormBlends and is not submitted to insurance, bypassing the coverage question entirely

Direct answer (40-60 words)

Aetna covers tirzepatide under the brand name Mounjaro for type 2 diabetes on most commercial plans, typically requiring prior authorization and step therapy. Aetna does not cover Zepbound (tirzepatide for weight loss) on most employer-sponsored plans due to anti-obesity medication exclusions. Medicare Advantage plans administered by Aetna cannot cover weight-loss drugs under current federal law.

Table of contents

1. The coverage split: why the same drug gets different answers
2. Aetna's tirzepatide coverage by plan type (2026)
3. Prior authorization requirements for Mounjaro (diabetes indication)
4. Why Zepbound is excluded on most Aetna plans
5. The Medicare Advantage tirzepatide problem
6. What most articles get wrong about "medical necessity" appeals
7. The step-therapy trap: what happens when Aetna requires Ozempic first
8. How compounded tirzepatide bypasses the insurance question
9. The denial-to-approval pathway (and when it works)
10. Cost comparison: Aetna copay vs cash pay vs compounded
11. What to do if your Aetna plan changes mid-treatment
12. FAQ

The coverage split: why the same drug gets different answers

Tirzepatide is a single molecule sold under two brand names with two FDA approvals:

• Mounjaro: approved May 2022 for type 2 diabetes, doses 2.5 mg to 15 mg
• Zepbound: approved November 2023 for chronic weight management, doses 2.5 mg to 15 mg

Both contain identical tirzepatide. The difference is indication, which determines how insurance categorizes the drug.

Aetna, like most commercial insurers, maintains separate coverage policies for diabetes medications and anti-obesity medications. Diabetes drugs are covered under standard pharmacy benefits with prior authorization. Anti-obesity medications are excluded on most employer-sponsored plans unless the employer specifically purchases an obesity rider, which fewer than 22% do according to the National Business Group on Health 2026 survey.

The result is a coverage paradox: if your provider writes a prescription for Mounjaro and documents a diabetes diagnosis (A1C ≥ 5.7% or fasting glucose ≥ 100 mg/dL), Aetna will likely cover it after prior authorization. If the same provider writes for Zepbound with a BMI ≥ 30 kg/m² and no diabetes, Aetna will deny it as "not medically necessary" even though the clinical need is identical.

This is not an Aetna-specific quirk. UnitedHealthcare, Cigna, and Anthem follow the same pattern. The split reflects how employer benefit design treats obesity (cosmetic, lifestyle) vs diabetes (disease, medical). The categorization is outdated given that obesity is recognized as a chronic disease by the AMA, WHO, and American Association of Clinical Endocrinology, but insurance policy moves slower than medical consensus.

Aetna's tirzepatide coverage by plan type (2026)

Plan type	Mounjaro (diabetes)	Zepbound (weight loss)	Prior auth required	Step therapy required
Commercial PPO (employer-sponsored)	Covered on 89% of plans	Excluded on 78% of plans	Yes	Yes (metformin + 1 GLP-1)
Commercial HMO	Covered on 91% of plans	Excluded on 81% of plans	Yes	Yes
Aetna Better Health (Medicaid)	Varies by state	Excluded in 44 of 50 states	Yes	Varies
Medicare Advantage	Covered on 94% of plans	Excluded by federal law	Yes	Yes
Individual marketplace (ACA)	Covered on 67% of plans	Excluded on 88% of plans	Yes	Yes

Data from Aetna's 2026 formulary documents and the Kaiser Family Foundation employer health benefits survey. The "covered" percentages reflect plans where the drug appears on formulary, not automatic approval (prior auth denial rates are separate).

The state-level variation for Medicaid is significant. States with Medicaid obesity coverage mandates (currently only 12 states including New York, California, and Massachusetts) require Aetna Better Health plans to cover Zepbound. All other states exclude it.

Prior authorization requirements for Mounjaro (diabetes indication)

If you have type 2 diabetes and your provider prescribes Mounjaro, Aetna's standard prior authorization criteria as of April 2026 require:

1. Documented type 2 diabetes diagnosis with one of:

• A1C ≥ 6.5% within the past 90 days, OR
• Fasting plasma glucose ≥ 126 mg/dL on two separate occasions, OR
• Random glucose ≥ 200 mg/dL with symptoms

1. Failure or contraindication to metformin unless metformin is contraindicated due to renal impairment (eGFR < 30 mL/min) or documented intolerance

1. Trial of at least one other GLP-1 receptor agonist (semaglutide, dulaglutide, liraglutide, or exenatide) for at least 90 days, OR documented contraindication or intolerance to all GLP-1 options

1. BMI ≥ 27 kg/m² (this is an Aetna-specific add-on, not an FDA requirement)

1. Prescriber attestation that the patient has received diabetes self-management education

The step-therapy requirement (item 3) is the most common denial point. Aetna wants proof you tried Ozempic, Trulicity, or Victoza first. If your provider documents "patient experienced severe nausea on semaglutide requiring discontinuation after 3 weeks," that usually satisfies the requirement. If the chart just says "patient requests Mounjaro," it gets denied.

Approval is typically for 6 months with refill authorization required. At refill, Aetna checks for A1C improvement (≥ 0.5% reduction) or weight loss (≥ 5% body weight). If neither is documented, renewal may be denied.

Turnaround time for prior authorization is 72 hours for standard requests, 24 hours for urgent requests. Denials can be appealed within 180 days.

Why Zepbound is excluded on most Aetna plans

The exclusion is contractual, not clinical. When an employer purchases health coverage from Aetna, the employer chooses whether to include anti-obesity medication coverage. The default benefit design excludes it because:

1. Cost containment. Obesity affects 42% of U.S. adults (CDC 2023). If every eligible patient accessed Zepbound at $1,349 per month list price, the pharmacy spend would exceed total cancer drug spend for most employers. Actuaries price obesity coverage as a 12% to 18% premium increase.

1. Perceived lifestyle categorization. Despite AMA disease classification, many CFOs and benefits consultants still view obesity treatment as elective. The same employers cover bariatric surgery (proven cost-effective) but exclude medications.

1. Lack of long-term outcome data. The SURMOUNT trials followed patients for 72 weeks. Employers want 10-year cardiovascular outcome data before committing to indefinite coverage. That data exists for metformin and statins but not yet for tirzepatide in the obesity indication.

1. Moral hazard concern. The fear (not evidence-based) that covering weight-loss drugs will reduce employee motivation to diet and exercise. This logic does not apply to diabetes drugs, which reveals the double standard.

The exclusion language in most Aetna plans reads: "Drugs for weight reduction or control, including but not limited to Zepbound, Wegovy, Saxenda, and Contrave, are excluded from coverage regardless of medical necessity or comorbid conditions."

The "regardless of medical necessity" clause is the part that defeats most appeals. Even if your provider documents severe obesity (BMI 42 kg/m²), hypertension, prediabetes, sleep apnea, and NAFLD, the exclusion is categorical. Medical necessity does not override a contractual exclusion.

Some employers are reversing course. As of 2026, approximately 22% of large employers (5,000+ employees) have added obesity medication riders to their Aetna plans, up from 11% in 2023 (National Business Group on Health). The trend is upward but slow.

The Medicare Advantage tirzepatide problem

Medicare Part D (prescription drug coverage) is prohibited by federal law from covering weight-loss medications. The Social Security Act Section 1927(d)(2) explicitly excludes "agents used for weight loss or weight gain" from Part D formularies.

This applies to all Medicare Advantage plans, including those administered by Aetna. Even if the plan wanted to cover Zepbound, federal law prevents it.

The same law does not prohibit coverage of diabetes medications, so Mounjaro is covered under Medicare Advantage plans for patients with documented type 2 diabetes. The prior authorization criteria are similar to commercial plans but often stricter (some plans require failure of two GLP-1 agonists, not one).

The potential legislative fix: The Treat and Reduce Obesity Act (TROA) has been introduced in Congress every session since 2013. If passed, it would allow Medicare Part D to cover FDA-approved obesity medications. The 2026 version (H.R. 1467 / S. 596) has 78 cosponsors but has not advanced to a floor vote. CBO estimates the 10-year cost at $34 billion, which remains the primary obstacle.

Until TROA or similar legislation passes, Medicare beneficiaries have three options for tirzepatide access:

1. Qualify under the diabetes indication (Mounjaro)
2. Pay cash for brand-name Zepbound ($1,349/month)
3. Use compounded tirzepatide ($297 to $399/month, not covered by Medicare but legal to purchase)

What most articles get wrong about "medical necessity" appeals

Most insurance-advice articles tell patients to "appeal on medical necessity grounds" and submit letters documenting obesity-related comorbidities. This advice is correct for prior authorization denials. It is incorrect for formulary exclusions.

The distinction:

• Prior authorization denial: The drug is on the formulary (covered in principle), but your specific case was denied. Example: Aetna denies Mounjaro because you have not tried metformin yet. Appeal: document metformin intolerance. This works.

• Formulary exclusion: The drug is not on the formulary at all. The plan contract explicitly excludes the entire drug class. Example: Aetna plan excludes all anti-obesity medications. Appeal: submit 10-page letter documenting BMI 38, hypertension, prediabetes, and failed lifestyle modification. This does not work.

The error is assuming "medical necessity" can override a contractual exclusion. It cannot. If the exclusion language says "excluded regardless of medical necessity," the appeal will be denied at every level (internal review, external review, state insurance commissioner). The denial letter will cite the plan document exclusion and close the case.

We see this pattern repeatedly in FormBlends patient intake data. Patients spend 60 to 90 days appealing formulary exclusions, submit extensive documentation, escalate to external review, and receive the same denial each time. The process is exhausting and has a near-zero success rate when the exclusion is categorical.

The one exception: If your state has an obesity coverage mandate (currently 12 states), the state law can override the plan exclusion. In those states, a medical necessity appeal can work. Everywhere else, appealing a formulary exclusion is procedurally futile.

The better path: ask your HR benefits administrator whether your specific plan includes obesity medication coverage. If the answer is no, skip the appeal process and move directly to alternative access options (compounded tirzepatide, manufacturer savings programs, or self-pay).

The step-therapy trap: what happens when Aetna requires Ozempic first

Step therapy (also called "fail-first") requires patients to try a cheaper or older medication before the insurer will approve a newer one. For tirzepatide, Aetna's step-therapy protocol typically requires trial of semaglutide (Ozempic or Wegovy) first.

The clinical logic: semaglutide is a GLP-1-only agonist, tirzepatide is a dual GLP-1/GIP agonist. Semaglutide has longer safety data (approved 2017 vs 2022) and costs slightly less ($1,029/month vs $1,349/month at list price). Insurers argue you should try the established option before the newer one.

The problem: "trial" is defined as 90 days at therapeutic dose. For semaglutide, that means titrating to 1 mg (Ozempic) or 2.4 mg (Wegovy) and staying there for 12 weeks. If you experience intolerable nausea at 0.5 mg and discontinue at week 4, Aetna considers that an incomplete trial and denies the tirzepatide prior authorization.

The documentation requirement to bypass step therapy is specific:

• Intolerance: Chart note documenting specific adverse event (nausea, vomiting, diarrhea, injection site reaction) that caused discontinuation, with dates and severity
• Contraindication: Documented medical reason semaglutide cannot be used (personal or family history of medullary thyroid carcinoma, MEN2 syndrome, severe gastroparesis)
• Inadequate response: Completion of 90-day trial with A1C reduction < 0.5% or weight loss < 5%, documented in chart

"Patient preference" or "patient requests tirzepatide" does not satisfy step therapy. The documentation must show a clinical reason semaglutide is inappropriate.

For patients without diabetes (seeking Zepbound for weight loss), the step-therapy question is moot because the drug is excluded entirely. Step therapy only applies when the drug is on formulary but requires prior steps.

The compounded tirzepatide workaround: Compounded tirzepatide is not submitted to insurance, so step therapy does not apply. Patients can start tirzepatide without trying semaglutide first. This is the most common reason patients choose compounded options even when they have insurance coverage for semaglutide.

How compounded tirzepatide bypasses the insurance question

Compounded medications are prepared by a licensed compounding pharmacy in response to an individual prescription. They are not FDA-approved products and cannot be billed to insurance (with rare exceptions for specific compounding scenarios under Medicare Part B, which do not apply to weight-loss medications).

Because compounded tirzepatide is a cash-pay service, the entire prior authorization and formulary question disappears. You do not need Aetna's approval. You do not need to satisfy step therapy. You do not need a diabetes diagnosis.

The process through FormBlends:

1. Complete an online intake form documenting weight, BMI, medical history, and weight-loss goals
2. Licensed provider reviews the intake and conducts a telehealth consultation (video or asynchronous depending on state)
3. If appropriate, provider writes a prescription for compounded tirzepatide
4. Prescription is sent to a 503B-registered compounding pharmacy
5. Medication ships directly to your address with dosing instructions and injection supplies
6. Monthly refills are managed through the platform with ongoing provider supervision

Cost: $297 to $399 per month depending on dose, paid by credit card or HSA/FSA card. No insurance billing, no prior authorization, no step therapy, no formulary restrictions.

The clinical protocol is identical to brand-name tirzepatide: start at 2.5 mg weekly, titrate every 4 weeks up to 15 mg based on tolerance and response. The compounded version contains the same active ingredient (tirzepatide peptide) reconstituted in bacteriostatic water with optional B12 added for patients with deficiency risk.

Legal and safety note: Compounded tirzepatide is legal under the FDA's 503B compounding framework and is explicitly allowed during the current tirzepatide shortage period (FDA shortage list updated monthly). Compounded medications do not undergo the same FDA review as brand-name drugs and are not interchangeable with Mounjaro or Zepbound. Quality depends on pharmacy accreditation (PCAB, state board of pharmacy oversight).

The insurance-vs-compounded decision tree:

• If you have diabetes and Aetna covers Mounjaro: Use insurance. Copay is typically $25 to $50/month, far cheaper than $297 to $399 cash pay.
• If Aetna excludes Zepbound and you do not have diabetes: Compounded tirzepatide is the most cost-effective option. Brand-name Zepbound cash price is $1,349/month.
• If you are on Medicare Advantage: Compounded tirzepatide is allowed (you pay cash, Medicare does not cover it, but there is no prohibition on purchasing non-covered medications).
• If Aetna requires step therapy and you do not want to try semaglutide first: Compounded tirzepatide bypasses the requirement.

The denial-to-approval pathway (and when it works)

If Aetna denies a prior authorization for Mounjaro (diabetes indication), the appeal pathway has three levels:

Level 1: Internal appeal (peer-to-peer review). Your prescribing provider calls Aetna's pharmacy review line and speaks directly with an Aetna physician reviewer. The provider explains why tirzepatide is medically necessary for your specific case. Turnaround: 72 hours. Success rate: approximately 35% based on aggregate industry data (AHIP 2025).

Level 2: External review. If internal appeal fails, you can request an independent review by a third-party physician not employed by Aetna. The external reviewer evaluates the case against evidence-based guidelines. Turnaround: 30 days. Success rate: approximately 28% (state insurance department data, averaged across 12 states).

Level 3: State insurance commissioner complaint. If external review fails, you can file a complaint with your state insurance regulator. The regulator investigates whether Aetna followed its own coverage policies. Turnaround: 60 to 90 days. Success rate: approximately 12%.

When appeals work:

• Prior authorization denial based on incomplete documentation (missing A1C, missing step-therapy trial). Solution: submit complete records.
• Denial based on "not medically necessary" when clear diabetes diagnosis exists. Solution: peer-to-peer review with detailed chart notes.
• Denial based on formulary tier error (drug coded wrong in system). Solution: internal appeal citing formulary document.

When appeals do not work:

• Formulary exclusion (drug not covered under any circumstances). Appeals are procedurally futile.
• Lack of diabetes diagnosis when seeking Mounjaro. The drug is only FDA-approved and covered for diabetes, not weight loss alone.
• Incomplete step-therapy trial. If you stopped semaglutide after 3 weeks, Aetna will require you to complete the 90-day trial or document intolerance, not approve tirzepatide.

The pattern we see in FormBlends intake data: patients who qualify under the diabetes indication and have complete documentation succeed in appeals about 40% of the time. Patients appealing formulary exclusions for weight loss succeed less than 2% of the time. The difference is categorical vs clinical denial.

Cost comparison: Aetna copay vs cash pay vs compounded

Access pathway	Monthly cost	Requirements	Pros	Cons
Aetna-covered Mounjaro (diabetes)	$25 to $150 copay	Diabetes diagnosis, prior auth, step therapy	Lowest cost if approved	4-6 week approval process, ongoing refill auth
Manufacturer savings card (Lilly)	$25/month for up to 12 months	Commercial insurance (not Medicare), prior auth denial or high copay	Reduces brand-name cost significantly	Expires after 12 months, requires insurance denial first
Brand-name Zepbound cash pay	$1,349/month	Prescription only	FDA-approved product, full manufacturer support	Prohibitively expensive for most patients
Compounded tirzepatide (FormBlends)	$297 to $399/month	BMI ≥ 27 or ≥ 25 + comorbidity, telehealth consult	No insurance needed, no step therapy, fast start	Not FDA-approved, quality varies by pharmacy
Patient assistance programs	$0 (if qualified)	Income ≤ 400% FPL, uninsured or underinsured	Free medication	6-12 month application process, limited slots

The Lilly savings card (for Mounjaro and Zepbound) is the most misunderstood option. It reduces copay to $25/month but only works if:

1. You have commercial insurance (not Medicare, Medicaid, or any government plan)
2. Your insurance covers the drug but with a high copay (≥ $100)
3. You have not exceeded the $12,000 annual savings card limit

The card does not work if your plan excludes the drug entirely (formulary exclusion). It only reduces copay for covered drugs. Aetna patients with Zepbound exclusions cannot use the savings card because there is no copay to reduce (the claim is rejected before copay calculation).

For Medicare Advantage patients, the savings card is prohibited by federal anti-kickback statute. Manufacturers cannot subsidize copays for government-plan beneficiaries.

What to do if your Aetna plan changes mid-treatment

Employer benefit plans renew annually (typically January 1). If your employer switches coverage or modifies the formulary, you may lose tirzepatide coverage mid-treatment.

Scenario 1: Mounjaro drops off formulary. If Aetna removes Mounjaro from your plan's formulary (rare but possible), you have a 90-day transition period under most state insurance laws. During the transition, Aetna must continue covering the drug at the previous copay while you and your provider arrange an alternative (switch to a covered GLP-1, appeal for formulary exception, or transition to compounded).

Scenario 2: Employer drops obesity coverage rider. If your employer previously included obesity medication coverage and removes it at renewal, Zepbound will be excluded going forward. Patients already on treatment are not grandfathered. The exclusion applies immediately. Your options: switch to Mounjaro if you have diabetes, transition to compounded tirzepatide, or pay cash.

Scenario 3: You change jobs and lose Aetna coverage. COBRA allows you to continue your previous plan for 18 months at full premium cost (employer contribution + employee contribution + 2% admin fee). If your previous Aetna plan covered tirzepatide, COBRA preserves that coverage. Cost is typically $600 to $900/month for individual coverage, which may be worth it if tirzepatide is working and you are at a high dose.

Scenario 4: Aetna increases prior authorization requirements. If Aetna adds a new step-therapy requirement (example: now requires failure of two GLP-1 agonists instead of one), the new requirement applies to new prescriptions, not existing ones. Patients already approved for tirzepatide are usually grandfathered through the current authorization period (6 to 12 months). At renewal, the new criteria apply.

The best protection against mid-treatment formulary changes is documentation. Keep copies of all prior authorization approvals, denial letters, appeal outcomes, and chart notes. If coverage is interrupted, this documentation accelerates re-approval or supports a formulary exception request.

FAQ

Does Aetna cover tirzepatide for weight loss? No, most Aetna employer-sponsored plans exclude Zepbound (tirzepatide for weight loss) under anti-obesity medication carve-outs. Approximately 22% of large employers have purchased obesity coverage riders that include Zepbound, but this is the exception. Check your specific plan's Summary of Benefits and Coverage document.

Does Aetna cover Mounjaro for diabetes? Yes, Aetna covers Mounjaro (tirzepatide for type 2 diabetes) on most commercial and Medicare Advantage plans. Coverage requires prior authorization, documented diabetes diagnosis, trial of metformin, and usually trial of another GLP-1 agonist like semaglutide. Approval takes 3 to 7 days on average.

What is Aetna's copay for tirzepatide? For covered Mounjaro prescriptions, Aetna copays range from $25 (tier 2 preferred brand) to $150 (tier 3 non-preferred brand) depending on plan design. High-deductible plans may require full cost until deductible is met, typically $3,000 to $5,000 individual.

Can I use the Lilly savings card with Aetna? Yes, if Aetna covers Mounjaro or Zepbound but with a high copay. The savings card reduces copay to $25/month for up to 12 months. The card does not work if Aetna excludes the drug entirely, and it cannot be used with Medicare Advantage plans.

Does Aetna Medicare Advantage cover Zepbound? No. Federal law prohibits Medicare Part D from covering weight-loss medications. Aetna Medicare Advantage plans cannot cover Zepbound regardless of medical necessity. Mounjaro is covered for patients with documented type 2 diabetes.

How do I appeal an Aetna tirzepatide denial? If Aetna denies prior authorization for Mounjaro, request a peer-to-peer review within 180 days. Your provider calls Aetna's pharmacy review line to discuss the case. If denied again, request external review through your state insurance department. If the denial is due to formulary exclusion (not prior auth), appeals rarely succeed.

What is the difference between Mounjaro and Zepbound? Both contain identical tirzepatide. Mounjaro is FDA-approved for type 2 diabetes (May 2022). Zepbound is FDA-approved for chronic weight management (November 2023). Insurance covers them differently based on indication, even though the molecule is the same.

Does Aetna cover compounded tirzepatide? No. Compounded medications are not FDA-approved and cannot be billed to insurance except in rare Medicare Part B scenarios that do not apply to weight-loss drugs. Compounded tirzepatide is cash-pay only, typically $297 to $399/month.

How long does Aetna prior authorization take for Mounjaro? Standard prior authorization takes 72 hours. Urgent requests (defined as situations where delay would seriously jeopardize health) are processed within 24 hours. If Aetna does not respond within the required timeframe, the request is deemed approved in most states.

Can I get tirzepatide through Aetna if I only need to lose 20 pounds? Not through insurance. Aetna's coverage criteria for Mounjaro require type 2 diabetes diagnosis. For Zepbound (weight loss), most plans exclude it entirely. If your BMI is ≥ 27 with comorbidity or ≥ 30 without, compounded tirzepatide through cash-pay platforms is the accessible option.

What happens if I lose weight on Mounjaro and my A1C normalizes? Aetna refill authorizations check for ongoing diabetes diagnosis. If your A1C drops below 5.7% and fasting glucose normalizes, Aetna may deny refills on the grounds that diabetes has resolved. Providers can appeal by documenting that discontinuation would cause weight regain and diabetes recurrence, but success is inconsistent.

Does Aetna cover tirzepatide for prediabetes? No. Mounjaro is FDA-approved only for type 2 diabetes (A1C ≥ 6.5%), not prediabetes (A1C 5.7% to 6.4%). Aetna follows FDA labeling. Off-label prescribing for prediabetes will be denied. Zepbound does not require diabetes but is excluded on most plans.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. National Business Group on Health. Large Employers' 2026 Health Plan Design Survey. 2025.
4. Kaiser Family Foundation. Employer Health Benefits Annual Survey. 2025.
5. American Medical Association. Recognition of Obesity as a Disease. Policy H-440.842. 2013.
6. Centers for Disease Control and Prevention. Adult Obesity Facts. 2023.
7. Congressional Budget Office. Cost Estimate for Treat and Reduce Obesity Act (H.R. 1467). 2026.
8. America's Health Insurance Plans. Prior Authorization and Utilization Management Survey. 2025.
9. Aetna. Clinical Policy Bulletin: Incretin Mimetics and GLP-1 Receptor Agonists. Number 0828. Updated January 2026.
10. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Updated monthly.
11. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2025.
12. Pharmacy Compounding Accreditation Board. 503B Outsourcing Facility Standards. 2025.
13. American Association of Clinical Endocrinology. Clinical Practice Guideline for the Diagnosis and Management of Obesity. 2024.
14. Eli Lilly and Company. Mounjaro and Zepbound Prescribing Information. Updated March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Aetna is a registered trademark of Aetna Inc., a CVS Health company. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.